GAMMA Investing’s Structure Therapeutics GPCR Stock Holding History

GAMMA Investing’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$26.8K	Buy	857 +21	+3%	+$985	﹤0.01%	2769
2026 Q2	$44.9K	Sell	836 -163	-16%	-$7.21K	﹤0.01%	2377
2026 Q1	$48.2K	Buy	999 +69	+7%	+$4.72K	﹤0.01%	2203
2025 Q4	$64.7K	Buy	930 +112	+14%	+$4.57K	﹤0.01%	1890
2025 Q3	$22.9K	Buy	818 +337	+70%	+$6.71K	﹤0.01%	2448
2025 Q2	$9.98K	Sell	481 -26	-5%	-$572	﹤0.01%	2806
2025 Q1	$8.78K	Sell	507 -642	-56%	-$15.7K	﹤0.01%	2810
2024 Q4	$31.2K	Buy	1,149 +1,122	+4,156%	+$39.8K	﹤0.01%	2020
2024 Q3	$1.19K	Buy	27 +11	+69%	+$425	﹤0.01%	3209
2024 Q2	$628	Buy	16 +6	+60%	+$246	﹤0.01%	3162
2024 Q1	$429	Buy	10 +1	+11%	+$42	﹤0.01%	3127
2023 Q4	$393	Buy	+9	New	+$516	﹤0.01%	3006

Other funds holding GPCR

PCA

Private Capital Advisors Darien, Connecticut $1.15B AUM 43.46% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing's GPCR Position: Q3 2026 in Review

GAMMA Investing increased its Structure Therapeutics (GPCR) stake by 2.5% in Q3 2026, buying an estimated $985 and bringing the position to 857 shares worth $26.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2769.

GAMMA Investing first reported a position in GPCR in Q4 2023 and has held it in 12 quarters since. The position peaked at $64.7K in Q4 2025. 3 funds tracked by Wall St. Rank hold GPCR as of Q3 2026.

GAMMA Investing held 857 shares of Structure Therapeutics worth $26.8K as of Q3 2026.
GAMMA Investing bought 21 Structure Therapeutics shares in Q3 2026, an estimated $985.
Structure Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2769 holding.
GAMMA Investing first reported a position in Structure Therapeutics in Q4 2023 and has held it in 12 quarters since.
GAMMA Investing's Structure Therapeutics position peaked at $64.7K in Q4 2025.
3 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.